Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: A follow-up of 136 patients

International Journal of Leprosy and Other Mycobacterial Diseases

Volumn 70, Issue 3, 2002, Pages 174-181

  Kaur, Inderjeet ^a   Dogra, Sunil ^a   Kumar, Bhushan ^a   Radotra, B D ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; MYCOBACTERIUM VACCINE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXFOLIATIVE DERMATITIS; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GRANULOMA; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; JAUNDICE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM; ONSET AGE; RELAPSE; SCAR FORMATION; SPUTUM SMEAR; TREATMENT OUTCOME; TREATMENT PLANNING; ULCER HEALING; URTICARIA; VACCINATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BACTERIAL VACCINES; BIOPSY; CHILD; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HAND DEFORMITIES, ACQUIRED; HUMANS; IMMUNOTHERAPY, ACTIVE; INDIA; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; WORLD HEALTH ORGANIZATION;

EID: 0036760598     PISSN: 0148916X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Anonymous. Response to treatment by multidrug regimens in the THELEP controlled clinical drug trials. Subcommittee on clinical trials of the chemotherapy of leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Lepr. Rev. 67 (1996) 260-279.
2. Brandsma, J. W., De Jong, N. and Tjepkema, T. Disability grading in leprosy; suggested modification to WHO disability grading form. Lepr. Rev. 57 (1986) 361-369.
3. Convit, J., Aranzazu, N. Ulrich, M., Pinardi, M. E., Reyes, O. and Alvardo, J. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda negative contacts. Int. J. Lepr. 50 (1982) 415-424.
4. De Sarkar, A., Kaur, I., Radotra, B. and Kumar, B. Impact of combined Mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int. J. Lepr. 69 (2001) 187-194.
5. Gilbody, J. S. Aspects of rehabilitation in leprosy. Int. J. Lepr. 60 (1992) 608-640.
6. Girdhar, B. K., Girdhar, A. and Kumar, A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr. Rev. 71 (2000) 144-153.
7. Ji, B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr. Rev. 69 (1998) 106-109.
8. Jopling, W. H. and McDougall, A. C. The disease. In: Handbook of Leprosy. 5th Edn. New Delhi: CBS Publishers, 1996, pp. 10-47.
9. Kar, H., Sharma, A. K, Misra, R. S., Beena, K. R., Zaheer, S. A., Mukherjee, R., Mukherjee, A., Parida, S. K., Walia, R., Nair, S. K. and Talwar, G. P. Reversal reactions in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate antileprosy vaccine, Mycobacterium w. Lepr. Rev. 64 (1993) 219-226.
10. Katoch, K., Katoch, V. M., Natrajan, M., Bhatia, A. S., Sreevatsa, Gupta, U. D., Sharma, V. D., Shivannavar, C. T., Patil, M. A. and Bhardwaj, V. P. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Int. J. Lepr. 63 (1995) 202-211.
11. Katoch, V. M., Katoch, K., Ramanathan, U., Sharma, V. D., Shivannavar, C. T., Datta, A. K. and Bhardwaj, V. P. Effects of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological index and FDA-EB fluorescent staining. Int. J. Lepr. 57 (1989) 615-621.
12. Lockwood, D. N. J., Vinayakumar, S., Stanley, J. N. A., McAdam, P. W. J. and Colston, M. J. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int. J. Lepr. 61 (1993) 8-15.
13. Manandhar, R., Le Master, J. W. and Roche, P. W. Risk factors for erythema nodosum leprosum. Int. J. Lepr. 67 (1999) 270-278.
14. Marchoux Chemotherapy Study Group. Relapses in multibacillary leprosy patients after stopping treatment with rifampicin continuing combined regimens. Int. J. Lepr. 60 (1992) 525-535.
15. Mukherjee, A., Zaheer, S. A., Sharma, A. K., Misra, R. S., Kar, H. K., Mukherjee, R. and Talwar, G. P. Histopathological monitoring of immunotherapeutic trial with Mycobacterium w. Int. J. Lepr. 60 (1992) 28-35.
16. Nery, J. A., Viera, L. M. M. and de Matos, H. J. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev. Inst. Med. Trop. Sao Paulo 40 (1998) 363-370.
17. Pattyn, S. R., Groenen, G., Janssens, L., Deverchin, J. and Ghys, P. Combined regimens of one year duration in the treatment of multibacillary leprosy - II. Combined regimens with rifampicin administered during 6 months. Lepr. Rev. 60 (1989) 118-123.
18. Saunderson, P., Gebore, S. and Byass, P. ENL reactions in multibacillary cases of the AMFES cohort in central Ethiopia: Incidence and risk factors. Lepr. Rev. 71 (2000) 318-324.
19. Scollard, D. M., Smith, T., Bahoopat, L., Theetranont, C., Rangdaeng, S. and Morens, D. M. Epidemiologic characteristics of leprosy reactions. Int. J. Lepr. 62 (1994) 559-567.
20. Sharma, P., Kar, H. K., Benna, K, R., Kaur, H. and Naryan, R. Disabilities in multibacillary leprosy patients; before, during and after multidrug therapy. Indian J. Lepr. 68 (1996) 127-136.
21. Sharma, P., Kar, H. K., Misra, R., Mukherjee, A., Kaur, H., Mukherjee, R. and Rani, R. Induction of lepromin positivity following immunochemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy; a report on hospital based clinical trial with the candidate antileprosy vaccine. Int. J. Lepr. 67 (1999) 259-269.
22. Sharma, P., Kar, H. K., Misra, R. S., Mukherjee, A., Kaur, H., Mukherjee, R. and Rani, R. Reactional states and neuritis in multibacillary leprosy patients following MDT with/without immunotherapy Mycobacterium w vaccine. Lepr. Rev. 71 (2000) 193-205.
23. Sharma, P., Kar, H. K., Misra, R. S., Mukerjee, R. and Rani, R. Disabilities in multibacillary following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int. J. Lepr. 67 (1999) 250-258.
24. Sharma, P., Mishra, R. S., Kar, H. K., Mukherjee, A., Poricha, D., Kaur, H., Mukherjee, R. and Rani, R. Mycobacterium w vaccine, a useful adjuvant to multi-drug therapy in multi-bacillary leprosy. A report on hospital based immuno-therapeutic clinical trial with a follow up of 1-7 years after treatment. Lepr. Rev. 71 (2000) 179-192.
25. Sreevatsa, Girdhar, B. K. and Desikan, K. V. Screening of drug resistant strains of Mycobacterium leprae in lepromatous leprosy patients under multidrug therapy. Indian J. Med. Rev. 87 (1988) 139-143.
26. Talwar, G. R, Zaheer, S. A., Mukherjee, R., Walia, R., Misra, R. S., Sharma, A. K., Kar, H. K., Mukerjee, K., Parida, S. K., Suresh, N. R., Nair, S. K. and Pandey, R. M. Immunotherapeutic effects of vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w, in multibacillary leprosy patients. Vaccine 8 (1990) 121-129.
27. Van Brakel, W., Kist, P., Noble, S. and O'Toole, L. Relapses after multidrug therapy: A preliminary report of 22 cases in West Nepal. Lepr. Rev. 60 (1989) 45-50.
28. Van Brakel, W. H. Proposal regarding MB MDT. Lepr. Rev. 70 (1999) 71-73.
29. Walia, R., Sarthchandra, K. G., Pandey, R. M., Parida, S. K., Zaheer, S. A., Kar, H. K. and Mukherjee, A. Field trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes. Lepr. Rev. 64 (1993) 302-311.
30. Waters, M. F. R. Commentary. Is it safe to shorten multidrug therapy for lepromatous (LL & BL) leprosy to 12 months? Lepr. Rev. 69 (1998) 110-111.
31. WHO Expert Committee On Leprosy, Seventh Report. WHO Technical Report Series No. 874. Geneva: World Health Organization, 1998.
32. WHO Study Group. Chemotherapy of leprosy for control programmes. Geneva: World Health Organization, 1982. Tech. Rep Ser. 675.
33. World Health Organization. Progress towards the elimination of leprosy as a public health problem. Weekly Epidemol. Rec. 68 (1993) 181-188.
34. Zaheer, S. A., Beena, K. R., Kar, H. K., Sharma, A. K., Misra, R. S., Mukherjee, A., Mukherjee, R., Kaur, H., Pandey, R. M., Walia, R., Mukhopadhyay and Talwar, G. P. Addition of immunotherapy with Mycobacterium w vaccine to MDT benefits multibacillary leprosy patients. Vaccine 13 (1995) 1102-1110.
35. Zaheer, S. A., Misra, R. S., Sharma, A. K., Beena, K. R., Kar, H. K. and Mukherjee, A. Combined multidrug and mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167 (1993) 401-410.
36. Zaheer, S. A., Misra, R. S., Sharma, A. K., Beena, K. R., Kar, H. K., Mukherjee, A., Walia, R. and Talwar, G. P. Immunotherapy with Mycobacterium w vaccine decreases the incidence and severity of type 2 (ENL) reactions. Lepr. Rev. 64 (1993) 7-14.